



Biotech Daily

Wednesday June 2, 2021

Daily news on ASX-listed biotechnology companies

Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved

[ACTINOGEN MEDICAL](#)

Actinogen says it has ethics approval for its 100-healthy older volunteer, part-A Xanamia dosing study of Xanamem for cognition.

Actinogen said the Bellberry Human Research Ethics Committee approved the enrolment of patients expected to begin next month.

The company said part-A would be a dose-ranging study with Xanamem doses of 5mg and 10mg, at four clinics in Australia enrolling volunteers aged 50 years and above, to confirm the minimum effective dose.

Actinogen said the part-B study would assess the efficacy of the minimum dose and would be conducted with patients with mild cognitive impairment, due to biomarker-positive, early-stage Alzheimer's disease.

Actinogen was up 2.5 cents or 23.8 percent to 13 cents with 28.3 million shares traded.